Financial Survey: Connect Biopharma (CNTB) versus Its Rivals

Connect Biopharma (NASDAQ:CNTB) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Connect Biopharma to related businesses based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Connect Biopharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	2	1	2.75
Connect Biopharma Competitors	5558	12063	37477	1138	2.61

Connect Biopharma currently has a consensus target price of $8.50, suggesting a potential upside of 300.94%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 59.34%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than its competitors.

Valuation & Earnings

This table compares Connect Biopharma and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Connect Biopharma	$1.97 million	-$15.63 million	-5.05
Connect Biopharma Competitors	$974.60 million	-$45.55 million	11.59

Connect Biopharma’s competitors have higher revenue, but lower earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Connect Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Connect Biopharma Competitors	-1,415.95%	-736.08%	-28.61%

Volatility & Risk

Connect Biopharma has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Connect Biopharma’s competitors have a beta of 1.04, indicating that their average share price is 4% more volatile than the S&P 500.

Summary

Connect Biopharma beats its competitors on 9 of the 13 factors compared.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.